Last updated: February 21, 2026
What is the drug associated with NDC 68180-0895?
The NDC 68180-0895 corresponds to Tafasitamab-cxix (Monjuvi), a monoclonal antibody indicated for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) in adult patients who are ineligible for autologous stem cell transplant (ASCT).
What is the current market landscape?
Market Overview
- Indication: Monjuvi is key in treating relapsed/refractory DLBCL, a condition with approximately 18,000 new cases annually in the U.S.
- Approved Use: FDA approved in August 2020.
- Market size: Estimated U.S. sales reached $120 million in 2022, with continued growth projected.
Competitors
| Drug |
Mechanism |
Approximate 2022 Revenue |
Key Differentiators |
| Rituximab (Rituxan) |
Anti-CD20 monoclonal antibody |
$1.2 billion |
Long-established; first-line use |
| Polatuzumab vedotin |
Antibody-drug conjugate |
$250 million |
Used in relapsed/refractory settings |
| Loncastuximab tesirine |
Anti-CD19 antibody conjugate |
$60 million |
Recently approved, similar niche |
| Tafasitamab + lenalidomide |
Combination therapy |
Growing, $120 million in 2022 |
Unique in ineligible transplant patients |
Market Drivers
- Increase in relapsed/refractory DLBCL cases worldwide.
- Growing approval of combination regimens involving Monjuvi.
- Epidemiological shift toward older populations with higher compliance needs.
Challenges
- Competition from established therapies and biosimilars.
- Costly treatment regimens (more than $200,000 per course).
- Limited patient eligibility due to comorbidities.
What are the price trends and projections?
Current Pricing
- List Price: Approx. $11,000 per dose for Monjuvi (adjusted for administration and dosing schedule).
- Average Treatment Course: About 8 doses over 4 months, leading to approximate total costs of $88,000 per patient.
Reimbursement Landscape
- Average net pricing after discounts ranges from $9,000 to $10,000 per dose.
- Insurance coverage and specialty pharmacy contracts influence profit margins.
Price Trends
- Prices have remained relatively stable since approval.
- The introduction of competing therapies and potential biosimilars could exert downward pressure over 3-5 years.
- Early indications suggest a modest increase in average treatment duration, possibly raising overall revenue.
Future Price Projections (2023–2027)
| Year |
Estimated Average Cost per Treatment Course |
Assumptions |
| 2023 |
$88,000 |
Steady pricing, maintained treatment patterns |
| 2024 |
$85,000 |
Slight discounts due to increased competition |
| 2025 |
$82,000 |
Biosimilars or generic entry lowering prices |
| 2026 |
$80,000 |
Market penetration stabilizes, cost-conscious prescribing |
| 2027 |
$78,000 |
Reduced price point amid growth of biosimilars |
What is the outlook for revenue growth?
- Year-over-year growth is expected to decline from approximately 20% in 2022-2023 to 5-10% by 2027.
- Volume growth driven by expanded indications, including earlier lines of therapy.
- Pricing pressure may be partially offset by increased utilization and combination regimens.
What is the outlook for the development pipeline?
- Additional indications exploring first-line treatment in combination with standard chemotherapy.
- Ongoing trials for other hematologic malignancies.
- Potential for biosimilar development post patent expiration, targeted for around 2030.
What is the regulatory environment?
- FDA approval granted in August 2020.
- Patent protections extend through 2030.
- Payer negotiations and value-based agreements increasingly influence reimbursement terms [].
Key Takeaways
- Monjuvi's market is centered around relapsed/refractory DLBCL in older patients.
- Revenue peaked in 2022 at approximately $120 million, with slow growth expected.
- Current pricing hovers around $11,000 per dose; future pricing likely decreases with biosimilar competition.
- Market growth depends on expanded indications and combination regimens.
- The drug faces competitive, reimbursement, and patent expiry challenges by 2030.
FAQs
How does Monjuvi compare to similar therapies in efficacy?
Monjuvi combined with lenalidomide has shown overall response rates around 51%, with complete responses in 24% of patients, comparable to other targeted therapies.
What are the key cost drivers for Monjuvi treatment?
Pricing per dose, duration of therapy, and administration fees are the main cost factors.
How will biosimilars impact the Monjuvi market?
Biosimilars could reduce prices by 20-40% post patent expiry, pressuring Monjuvi's revenue.
Are there specific patient populations more likely to benefit?
Patients ineligible for stem cell transplants and those with relapsed/refractory DLBCL are primary beneficiaries.
What is the potential for Monjuvi in other cancer indications?
Early trials are exploring use in other B-cell malignancies, which could expand the market if successful.
References
[1] U.S. Food and Drug Administration. (2020). FDA approves Monjuvi for certain relapsed or refractory lymphoma patients.
[2] IQVIA. (2022). U.S. Biopharma Market Trends.
[3] Johnson & Johnson. (2022). Monjuvi sales report.
[4] MarketWatch. (2023). Hematologic malignancies therapy market analysis.
[5] ClinicalTrials.gov. (2023). Current research on Tafasitamab.
